Artiva Biotherapeutics (NASDAQ:ARTV) Issues Earnings Results

Artiva Biotherapeutics (NASDAQ:ARTV) released its earnings results on Tuesday. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24), Zacks reports.

Artiva Biotherapeutics Stock Performance

ARTV stock traded down $0.49 during trading on Thursday, reaching $11.21. 7,587 shares of the company’s stock were exchanged, compared to its average volume of 138,617. Artiva Biotherapeutics has a 1-year low of $9.68 and a 1-year high of $17.31. The company has a fifty day simple moving average of $12.60.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on ARTV. Jefferies Financial Group started coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating and a $21.00 price objective for the company. Wedbush reaffirmed an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, August 30th. TD Cowen initiated coverage on Artiva Biotherapeutics in a report on Tuesday, August 13th. They issued a “buy” rating on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday. Finally, Cantor Fitzgerald initiated coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $23.00 price target for the company. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.